GlassScriptPhysician profile
Jennifer M Owen
NPI 1578992285
$4,797.16
in general payments reported to CMS, 2019-2025
34 companies · $1,139 in 2025
The $1,139 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.33 · 2022: $924 · 2023: $1,600 · 2024: $1,123 · 2025: $1,139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,862.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,861.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,127.29 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $1,024.32 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $474.37 | 2022-2024 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $446.52 | 2022-2025 | |
| Abbvie INC. | $222.34 | 2022-2025 | |
| Amgen INC. | $197.39 | 2022-2025 | Repatha, Otezla, Evenity |
| Exact Sciences Corporation | $114.71 | 2023-2025 | Cologuard Collection Kit |
| Inspire Medical Systems, INC. | $98.77 | 2023-2025 | Inspire |
| Dexcom, INC. | $90.00 | 2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $80.14 | 2023-2025 | Veozah |
| Phathom Pharmaceuticals, INC. | $78.72 | 2023-2024 | Voquezna |
| Pulmonx Corporation | $75.31 | 2025 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Biohaven Pharmaceutical Holding Company LTD. | $73.54 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.67 | 2023-2025 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $64.07 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $62.16 | 2022-2023 | Belsomra, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.29 | 2022-2024 | |
| Radius Health, INC. | $47.33 | 2025 | |
| Dynavax Technologies Corporation | $42.05 | 2023-2024 | Heplisav-B |
| Boston Scientific Corporation | $33.93 | 2023 | Watchman Flx |
| Janssen Pharmaceuticals, INC | $33.78 | 2022 | |
| Axsome Therapeutics, INC. | $32.48 | 2025 | Auvelity |
| Kowa Pharmaceuticals America, INC. | $26.10 | 2022-2025 | Zoryve |
| Edwards Lifesciences Corporation | $24.37 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.28 | 2024 | |
| Eisai INC. | $24.20 | 2025 | |
| Alnylam Pharmaceuticals INC. | $24.09 | 2023 | Givlaari |
| Sumitomo Pharma America, INC. | $23.94 | 2023 | Gemtesa |
| Xeris Pharmaceuticals, INC. | $23.28 | 2025 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $23.18 | 2022 | |
| Medtronic, INC. | $16.96 | 2023 | Closurefast |
| Philips North America LLC | $15.04 | 2024 | (Ck7) Extended Holter |
| E.R. Squibb & Sons, L.L.C. | $13.21 | 2023 | Eliquis |
| Abiomed | $11.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Owen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.